Tela Bio Inc

NASDAQ TELA

Data sourced from

and

Daily

Download Data

Tela Bio Inc Price to Earnings Ratio (P/E) on June 03, 2024: -12.57

Tela Bio Inc Price to Earnings Ratio (P/E) is -12.57 on June 03, 2024, a -174.46% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.

Tela Bio Inc 52-week high Price to Earnings Ratio (P/E) is -3.19 on November 13, 2023, which is 74.63% above the current Price to Earnings Ratio (P/E).
Tela Bio Inc 52-week low Price to Earnings Ratio (P/E) is -14.53 on May 16, 2024, which is -15.64% below the current Price to Earnings Ratio (P/E).
Tela Bio Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is -5.36.

NASDAQ: TELA

Tela Bio Inc

CEO	Mr. Antony Koblish
IPO Date	Nov. 8, 2019
Location	United States
Headquarters	1 Great Valley Parkway, Malvern, PA, United States, 19355
Employees	227
Sector	Healthcare
Industry	Medical devices

Description

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Key trends